R
Raymond J. Hohl
Researcher at Penn State Cancer Institute
Publications - 185
Citations - 7555
Raymond J. Hohl is an academic researcher from Penn State Cancer Institute. The author has contributed to research in topics: Geranylgeranylation & Farnesyl pyrophosphate. The author has an hindex of 41, co-authored 178 publications receiving 6911 citations. Previous affiliations of Raymond J. Hohl include University of Iowa & Roy J. and Lucille A. Carver College of Medicine.
Papers
More filters
Journal ArticleDOI
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
W. K. A. Yung,Robert E. Albright,Jeffrey J. Olson,R Fredericks,Karen Fink,Michael D. Prados,Michael Brada,Alexander M. Spence,Raymond J. Hohl,William R. Shapiro,Michael Glantz,Harry S. Greenberg,Robert G. Selker,Nicholas A. Vick,R. Rampling,Henry S. Friedman,Peter C. Phillips,Janet M. Bruner,N. Yue,David Osoba,S Zaknoen,Victor A. Levin +21 more
TL;DR: Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 months in the PCB group, and freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received.
Journal ArticleDOI
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Judith E. Karp,Jeffrey E. Lancet,Scott H. Kaufmann,David W. End,John J. Wright,Kees Bol,Ivan Horak,Michael L. Tidwell,Jane L. Liesveld,Timothy Kottke,Dawn Ange,Laxmi Narayana Buddharaju,Ivana Gojo,W. Edward Highsmith,Robert T. Belly,Raymond J. Hohl,Mary Ellen Rybak,Alain Thibault,Joseph D. Rosenblatt +18 more
TL;DR: The results of this first clinical trial of a signal transduction inhibitor in patients with acute leukemias suggest that inhibitors of FT may have important clinical antileukemic activity.
Journal Article
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
Alain Thibault,Dvorit Samid,Dvorit Samid,Anne Tompkins,William D. Figg,Michael R. Cooper,Michael R. Cooper,Raymond J. Hohl,Jane B. Trepel,Bertrand C. Liang,Nicholas J. Patronas,David Venzon,Eddie Reed,Charles E. Myers,Charles E. Myers +14 more
TL;DR: Treatment with ubiquinone was associated with reversal of lovastatin-induced myopathy, and its prophylactic administration prevented the development of this toxicity in a cohort of 56 patients.
Journal ArticleDOI
O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Joshua D. Schoenfeld,Zita A. Sibenaller,Kranti A. Mapuskar,Brett A. Wagner,Kimberly L. Cramer-Morales,Muhammad Furqan,Sonia Sandhu,Thomas L. Carlisle,Mark C. Smith,Taher Abu Hejleh,Daniel J. Berg,Jun Zhang,John Keech,Kalpaj R. Parekh,Sudershan K. Bhatia,Varun Monga,Kellie L. Bodeker,Logan Ahmann,Sandy Vollstedt,Heather Brown,Erin P. Shanahan Kauffman,Mary E. Schall,Raymond J. Hohl,Gerald H. Clamon,Jeremy D.W. Greenlee,Matthew A. Howard,Michael K. Schultz,Brian J. Smith,Dennis P. Riley,Frederick E. Domann,Joseph J. Cullen,Garry R. Buettner,John M. Buatti,Douglas R. Spitz,Bryan G. Allen +34 more
TL;DR: It is shown that alterations in cancer cell mitochondrial oxidative metabolism resulting in increased levels of O2⋅- and H2O2 are capable of disrupting intracellular iron metabolism, thereby selectively sensitizing non-small-cell lung cancer and glioblastoma cells to ascorbate through pro-oxidant chemistry involving redox-active labile iron and H 2O2.
Journal ArticleDOI
Isoprenoids: Remarkable diversity of form and function
TL;DR: This review focuses on C-10 mono-, C-15 sesqui-, and C-20 diterpenes, and the diverse functions of these molecules, including their ability to regulate expression of the β-HMG-CoA reductase and Ras-related proteins.